Uploaded August 2026 | Updated September 2026, 2 weeks ago

---

Campaigners advocating for those affected by Friedreich's Ataxia have again appealed to the HSE to approve the Skyclarys treatment ahead of a final decision next week.

Friedreich's Ataxia is a rare progressive neuromuscular condition affecting around 200 people in Ireland.

At the current listed price, Skyclarys would cost around €280,000 per patient per year, with a five-year budget impact of around €130m.

For more on this story and all the latest Irish and international news - http://www.rte.ie/news

Thanks for watching and don't forget to subscribe.